drugset / Trial / NCT04273607

Anticoagulation-free VV ECMO for Acute Respiratory Failure

NCT04273607

RandomizedParallel-groupOpen-labelTreatment

Summary

Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an "anticoagulation-free strategy" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).

Timeline

Start
2022-09-01
Primary completion
2026-12-31
Completion
2027-01-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Heparin Other / unclassified Subcutaneous

Indications

No indication recorded.